AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central ...

AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi.

AbbVie received approval from Health Canada from Elahere, an antibody-drug conjugate for treating adults with ovarian, fallopian tube or peritoneal cancer. Elahere was approved through priority review ...

Trying to decide whether to hold, sell, or even start a position in AbbVie right now? You are not alone. This stock has a way ...

AbbVie is trying to put humanity first in its recently-launched I Am campaign, which was achieved in partnership with agency Prophet.

You might think that stocks with high dividend yields wouldn't be in that group. After all, such dividends can often be ...

Plexium has raised $60.1 million, providing an infusion of cash for the r | Plexium has raised $60.1 million, providing an ...

Health Canada has granted a Notice of Compliance (NOC) to AbbVie’s Rinvoq (upadacitinib) to treat adult patients diagnosed with chronic autoimmune vasculitis, giant cell arteritis (GCA).

2021 was a wild year for the biotech public stock market. Across the U.S. and Europe, more than 100 startups went for their ...

AbbVie will acquire Gilgamesh’s experimental antidepressant bretisilocin for up to $1.2 billion, aiming to bolster its ...